<h4>Background</h4>Despite the widespread use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), many patients with diabetic kidney disease continue to exhibit persistent proteinuria, highlighting an unmet clinical need for effective add-on therapies. This evidence concerns the gene SLC5A2 and diabetic kidney disease.